Title : Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.

Pub. Date : 2015

PMID : 26018524






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The ERBB2 inhibitor TAK-165 was synergistic with trametinib in KRAS-mutant cell lines. TAK-165 KRAS proto-oncogene, GTPase Homo sapiens